| Current Price | $203.86 | Mkt Cap | $75.2B |
|---|---|---|---|
| Open | $198.98 | P/E Ratio | 38.18 |
| Prev. Close | $203.86 | Div. (Yield) | $2.78 (1.4%) |
| Daily Range | $197.24 - $204.16 | Volume | 1,976,558 |
| 52-Wk Range | $193.34 - $281.16 | Avg. Daily Vol. | 1,356,305 |
A medical technology company in orthopaedics products. Its products include implants, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation.
| Current Price | $203.86 | Mkt Cap | $75.2B |
|---|---|---|---|
| Open | $198.98 | P/E Ratio | 38.18 |
| Prev. Close | $203.86 | Div. (Yield) | $2.78 (1.4%) |
| Daily Range | $197.24 - $204.16 | Volume | 1,976,558 |
| 52-Wk Range | $193.34 - $281.16 | Avg. Daily Vol. | 1,356,305 |
The best Bull and Bear pitches based on recency and number of recommendations.
About half of Stryker's revenue comes from reconstructive orthopedic implants, where the firm is a top-tier provider of knees and hips. Demographic trends of obesity and increased life span.Stock price has gone net nowhere since 2004, as eps… More
With rising unemployment and subsequent loss of health insurance, people are putting off elective hip and knee surgery which adversely affects Stryker.Also, chief executive Stephen MacMillan recently backed off from giving any long term sales and… More
Read the most recent pitches from players about SYK.
Recs
TMFkodyk123
(72.65)
Submitted: 7/31/2021 11:53:48 PM :
Start Price:
$267.08
NYSE:SYK Score:
-10.51
While not a bargain at 29 times this year's midpoint earnings figure of $9.33, SYK isn't expensive either. Analysts estimate that SYK will generate annual earnings growth in the low-teens over the next 5 years, which seems reasonable given the massive backlog of elective procedures stemming from COVID and recent product launches.
Recs
Dividends500
(92.84)
Submitted: 12/25/2020 8:47:12 AM :
Start Price:
$206.12
NYSE:SYK Score:
-20.38
Dividends500 tracks the healthiest dividends in the S&P 500.
To qualify for the portfolio, the company must meet three simple requirements:
- Member of the S&P 500
- Payout ratio below 50%
- Dividend growth year over year
Recs
R0cketi3
(< 20)
Submitted: 10/20/2020 11:26:28 AM :
Start Price:
$220.43
NYSE:SYK Score:
-18.83
One of the leaders in joint replacement. An area where there is plenty of demand. I'd say pent up demand these days as patients are reluctant to have these procedures.
Find the members with the highest scoring picks in SYK.
wooderino (83.51) Score: +370.17
The Score Leader is the player with the highest score across all their picks in SYK.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
|
db74006 | 60.90 | 3/23/2009 |
|
NS | $26.88 | +656.12% | +383.50% | +272.62 | 0 Comment |
| Xitopie | < 20 | 4/3/2009 |
|
5Y | $28.05 | +624.41% | +358.31% | +266.10 | 1 Comment | |
| Moreliator | 45.01 | 3/23/2009 |
|
3Y | $27.41 | +641.41% | +381.15% | +260.26 | 1 Comment | |
| bejeweledfool | < 20 | 4/6/2009 |
|
5Y | $28.15 | +621.80% | +362.14% | +259.66 | 0 Comment | |
| saaf569 | 26.05 | 3/23/2009 |
|
3Y | $27.16 | +648.34% | +389.34% | +259.00 | 0 Comment | |
| tpulley | 45.15 | 3/23/2009 |
|
NS | $27.16 | +648.34% | +389.34% | +259.00 | 1 Comment | |
| MaxPower13 | 97.48 | 4/6/2009 |
|
5Y | $28.04 | +624.84% | +366.61% | +258.23 | 0 Comment | |
| chaddodson | 72.25 | 4/7/2009 |
|
3Y | $28.02 | +625.29% | +367.97% | +257.31 | 0 Comment | |
| MuhaPSU | 97.87 | 4/7/2009 |
|
5Y | $27.93 | +627.48% | +372.05% | +255.44 | 0 Comment | |
|
|
tacross3 | 51.82 | 4/8/2009 |
|
3Y | $28.18 | +621.14% | +369.52% | +251.62 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
